Published in J Med Chem on October 30, 2007
targetTB: a target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis. BMC Syst Biol (2008) 1.84
Engineering the substrate specificity of the DhbE adenylation domain by yeast cell surface display. Chem Biol (2013) 1.51
Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5'-O-[N-(salicyl)sulfamoyl]adenosine. J Med Chem (2008) 1.40
Novel acyl phosphate mimics that target PlsY, an essential acyltransferase in gram-positive bacteria. ChemMedChem (2008) 1.31
Inhibition of siderophore biosynthesis by 2-triazole substituted analogues of 5'-O-[N-(salicyl)sulfamoyl]adenosine: antibacterial nucleosides effective against Mycobacterium tuberculosis. J Med Chem (2008) 1.21
Aryl acid adenylating enzymes involved in siderophore biosynthesis: fluorescence polarization assay, ligand specificity, and discovery of non-nucleoside inhibitors via high-throughput screening. Biochemistry (2008) 1.05
Biochemical and structural characterization of bisubstrate inhibitors of BasE, the self-standing nonribosomal peptide synthetase adenylate-forming enzyme of acinetobactin synthesis. Biochemistry (2010) 1.04
Self-poisoning of Mycobacterium tuberculosis by interrupting siderophore recycling. Proc Natl Acad Sci U S A (2014) 1.01
Adenylating enzymes in Mycobacterium tuberculosis as drug targets. Curr Top Med Chem (2012) 1.00
Small molecule inhibition of microbial natural product biosynthesis-an emerging antibiotic strategy. Chem Soc Rev (2008) 0.98
Targeting iron assimilation to develop new antibacterials. Expert Opin Drug Discov (2012) 0.97
A continuous kinetic assay for adenylation enzyme activity and inhibition. Anal Biochem (2010) 0.92
Iron trafficking as an antimicrobial target. Biometals (2009) 0.91
Characterization of peptide chain length and constituency requirements for YejABEF-mediated uptake of microcin C analogues. J Bacteriol (2011) 0.91
General platform for systematic quantitative evaluation of small-molecule permeability in bacteria. ACS Chem Biol (2014) 0.89
Mechanistic analysis of Mycobacterium tuberculosis Rv1347c, a lysine Nepsilon-acyltransferase involved in mycobactin biosynthesis. Arch Biochem Biophys (2008) 0.87
Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography. J Med Chem (2010) 0.84
Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors for Mycobacterium tuberculosis. J Med Chem (2015) 0.82
Synthesis of chromone, quinolone, and benzoxazinone sulfonamide nucleosides as conformationally constrained inhibitors of adenylating enzymes required for siderophore biosynthesis. J Org Chem (2013) 0.81
Quantitative three dimensional structure linear interaction energy model of 5'-O-[N-(salicyl)sulfamoyl]adenosine and the aryl acid adenylating enzyme MbtA. J Med Chem (2008) 0.80
Identification of inhibitors of PvdQ, an enzyme involved in the synthesis of the siderophore pyoverdine. ACS Chem Biol (2014) 0.80
Synthesis, biological evaluation, and structure-activity relationships of N-benzoyl-2-hydroxybenzamides as agents active against P. falciparum (K1 strain), Trypanosomes, and Leishmania. J Med Chem (2012) 0.80
Reaction intermediate analogues as bisubstrate inhibitors of pantothenate synthetase. Bioorg Med Chem (2014) 0.79
Investigation and conformational analysis of fluorinated nucleoside antibiotics targeting siderophore biosynthesis. J Org Chem (2015) 0.79
Expanding the results of a high throughput screen against an isochorismate-pyruvate lyase to enzymes of a similar scaffold or mechanism. Bioorg Med Chem (2014) 0.77
Synthesis and pharmacological evaluation of nucleoside prodrugs designed to target siderophore biosynthesis in Mycobacterium tuberculosis. Bioorg Med Chem (2016) 0.75
Active site-directed proteomic probes for adenylation domains in nonribosomal peptide synthetases. Chem Commun (Camb) (2015) 0.75
Models for antitubercular activity of 5â-O-[(N-Acyl)sulfamoyl]adenosines. Sci Pharm (2010) 0.75
2-Aryl-8-aza-3-deazaadenosine analogues of 5'-O-[N-(salicyl)sulfamoyl]adenosine: Nucleoside antibiotics that block siderophore biosynthesis in Mycobacterium tuberculosis. Bioorg Med Chem (2016) 0.75
Iron metabolism in pathogenic bacteria. Annu Rev Microbiol (2000) 7.91
Mycobactins: iron-chelating growth factors from mycobacteria. Bacteriol Rev (1970) 6.60
Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem Anal (2005) 5.37
Genetics and assembly line enzymology of siderophore biosynthesis in bacteria. Microbiol Mol Biol Rev (2002) 5.12
Enterobactin: an archetype for microbial iron transport. Proc Natl Acad Sci U S A (2003) 3.94
Identification of a Mycobacterium tuberculosis gene cluster encoding the biosynthetic enzymes for assembly of the virulence-conferring siderophore mycobactin. Chem Biol (1998) 3.89
Lack of a role for iron in the Lyme disease pathogen. Science (2000) 2.66
Enzymic activation and transfer of fatty acids as acyl-adenylates in mycobacteria. Nature (2004) 2.57
Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis. Nat Chem Biol (2005) 2.55
Crystal structure of DhbE, an archetype for aryl acid activating domains of modular nonribosomal peptide synthetases. Proc Natl Acad Sci U S A (2002) 2.51
Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis. J Med Chem (2006) 2.37
The dhb operon of Bacillus subtilis encodes the biosynthetic template for the catecholic siderophore 2,3-dihydroxybenzoate-glycine-threonine trimeric ester bacillibactin. J Biol Chem (2000) 2.12
Bacillus anthracis requires siderophore biosynthesis for growth in macrophages and mouse virulence. Mol Microbiol (2004) 2.12
Inhibition of aryl acid adenylation domains involved in bacterial siderophore synthesis. FEBS J (2006) 1.61
Aminoacyl tRNA synthetases as targets for new anti-infectives. FASEB J (1998) 1.54
Iron chelators from mycobacteria (1954-1999) and potential therapeutic applications. Nat Prod Rep (2000) 1.48
Versatile polyketide enzymatic machinery for the biosynthesis of complex mycobacterial lipids. Nat Prod Rep (2007) 1.46
Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain. J Med Chem (2006) 1.41
Bisubstrate inhibition: Theory and application to N-acetyltransferases. Biochemistry (2006) 1.32
Design, synthesis, and biological evaluation of beta-ketosulfonamide adenylation inhibitors as potential antitubercular agents. Org Lett (2006) 1.27
A mechanism-based aryl carrier protein/thiolation domain affinity probe. J Am Chem Soc (2007) 1.22
Characterization and analysis of early enzymes for petrobactin biosynthesis in Bacillus anthracis. Biochemistry (2007) 1.21
Reactions catalyzed by mature and recombinant nonribosomal peptide synthetases. Methods Enzymol (2004) 1.20
Aminoacyl-tRNA synthetases and their inhibitors as a novel family of antibiotics. Appl Microbiol Biotechnol (2003) 1.16
Synthesis and studies of catechol-containing mycobactin S and T analogs. Org Biomol Chem (2007) 1.02
A general synthesis of 5'-azido-5'-deoxy-2',3'-O-isopropylidene nucleosides. J Org Chem (2001) 0.88
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol (2009) 8.13
Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis (2012) 7.18
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet (2012) 6.78
A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature (2004) 6.29
Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med (2012) 5.87
Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun (2008) 4.93
The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem (2004) 4.75
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science (2008) 4.74
Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest (2008) 4.41
Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev Microbiol (2005) 4.38
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science (2011) 4.13
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 3.97
A pilot study of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillance. BMJ Open (2012) 3.93
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science (2009) 3.73
Age and the epidemiology and pathogenesis of tuberculosis. Lancet (2010) 3.37
DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell (2003) 3.36
Evolutionary dynamics of Staphylococcus aureus during progression from carriage to disease. Proc Natl Acad Sci U S A (2012) 3.29
Tuberculosis: what we don't know can, and does, hurt us. Science (2010) 3.29
Whole-genome sequencing shows that patient-to-patient transmission rarely accounts for acquisition of Staphylococcus aureus in an intensive care unit. Clin Infect Dis (2013) 3.05
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun (2005) 2.89
Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest (2009) 2.78
Campylobacter genotyping to determine the source of human infection. Clin Infect Dis (2009) 2.70
Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem (2003) 2.63
The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A (2003) 2.60
Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis (2012) 2.53
Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis (2005) 2.50
Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect Immun (2004) 2.47
The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated. J Bacteriol (2007) 2.42
SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 2.41
Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol (2004) 2.41
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc (2008) 2.37
Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis. J Med Chem (2006) 2.37
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol (2007) 2.26
Public perception of climate change voluntary mitigation and barriers to behavior change. Am J Prev Med (2008) 2.25
Genetic analysis of meningococci carried by children and young adults. J Infect Dis (2005) 2.12
Proteasomal protein degradation in Mycobacteria is dependent upon a prokaryotic ubiquitin-like protein. J Biol Chem (2008) 2.12
Mismatch induced speciation in Salmonella: model and data. Philos Trans R Soc Lond B Biol Sci (2006) 2.11
Microevolutionary analysis of Clostridium difficile genomes to investigate transmission. Genome Biol (2012) 2.04
Structural and functional investigation of the intermolecular interaction between NRPS adenylation and carrier protein domains. Chem Biol (2012) 1.99
The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J Biol Chem (2004) 1.99
Prospects for new antitubercular drugs. Curr Opin Microbiol (2004) 1.94
Public perception and behavior change in relationship to hot weather and air pollution. Environ Res (2008) 1.92
Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. J Bacteriol (2002) 1.86
Sequence-based analysis uncovers an abundance of non-coding RNA in the total transcriptome of Mycobacterium tuberculosis. PLoS Pathog (2011) 1.83
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol (2008) 1.73
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis (2009) 1.68
Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis (2008) 1.67
Within-host evolution of Staphylococcus aureus during asymptomatic carriage. PLoS One (2013) 1.67
High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem (2011) 1.64
Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol (2013) 1.62
Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. J Biol Chem (2003) 1.62
Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem (2008) 1.62
A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem Biol (2012) 1.59
Assigning the source of human campylobacteriosis in New Zealand: a comparative genetic and epidemiological approach. Infect Genet Evol (2009) 1.58
A comparative lipidomics platform for chemotaxonomic analysis of Mycobacterium tuberculosis. Chem Biol (2011) 1.56
Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology (2009) 1.54
The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol (2009) 1.53
Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol (2002) 1.52
Engineering the substrate specificity of the DhbE adenylation domain by yeast cell surface display. Chem Biol (2013) 1.51
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother (2011) 1.50
Genetic diversity of Mycobacterium tuberculosis isolates from a tertiary care tuberculosis hospital in South Korea. J Clin Microbiol (2009) 1.49
Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci U S A (2012) 1.48
Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog (2011) 1.45
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev (2015) 1.45
Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science (2012) 1.44
Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J Clin Microbiol (2009) 1.43
Broad-scale recombination patterns underlying proper disjunction in humans. PLoS Genet (2009) 1.42
Top down characterization of secreted proteins from Mycobacterium tuberculosis by electron capture dissociation mass spectrometry. J Am Soc Mass Spectrom (2003) 1.41
Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain. J Med Chem (2006) 1.41
Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5'-O-[N-(salicyl)sulfamoyl]adenosine. J Med Chem (2008) 1.40
Crystal structure of 4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate kinase from Salmonella typhimurium at 2.3 A resolution. Structure (2002) 1.39
A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc Natl Acad Sci U S A (2013) 1.39
Detection of mixed infection from bacterial whole genome sequence data allows assessment of its role in Clostridium difficile transmission. PLoS Comput Biol (2013) 1.38
In vivo phenotypic dominance in mouse mixed infections with Mycobacterium tuberculosis clinical isolates. J Infect Dis (2005) 1.36
Impact of diabetes and smoking on mortality in tuberculosis. PLoS One (2013) 1.36
Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother (2012) 1.32
Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One (2013) 1.31
Expansion of the mycobacterial "PUPylome". Mol Biosyst (2009) 1.31
Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol Microbiol (2012) 1.30